Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Lifecore Biomedical (LFCR) over the last 14 years, with May 2025 value amounting to -$3.5 million.

  • Lifecore Biomedical's Change in Accured Expenses fell 159.96% to -$3.5 million in Q2 2025 from the same period last year, while for May 2025 it was -$5.9 million, marking a year-over-year decrease of 458.08%. This contributed to the annual value of -$5.9 million for FY2025, which is 458.08% down from last year.
  • Per Lifecore Biomedical's latest filing, its Change in Accured Expenses stood at -$3.5 million for Q2 2025, which was down 294.92% from -$886,000 recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Change in Accured Expenses registered a high of $13.2 million during Q1 2023, and its lowest value of -$13.1 million during Q2 2023.
  • Over the past 3 years, Lifecore Biomedical's median Change in Accured Expenses value was -$1.1 million (recorded in 2024), while the average stood at -$411,300.
  • In the last 5 years, Lifecore Biomedical's Change in Accured Expenses skyrocketed by 380.75% in 2022 and then plummeted by 2,415.03% in 2023.
  • Quarterly analysis of 5 years shows Lifecore Biomedical's Change in Accured Expenses stood at -$2.0 million in 2021, then climbed by 9.60% to -$1.8 million in 2022, then soared by 86.11% to -$246,000 in 2023, then tumbled by 412.60% to -$1.3 million in 2024, then tumbled by 159.96% to -$3.5 million in 2025.
  • Its Change in Accured Expenses stands at -$3.5 million for Q2 2025, versus -$886,000 for Q1 2025 and -$1.3 million for Q4 2024.